Eptifibatide Dipyridamole

Clinically important, potentially hazardous interactions with abciximab, anagrelide, anticoagulants, cilostazol, clopidogrel, dabigatran, dipyridamole, eptifibatide, salicylates, ticlopidine, tirofiban. Many herbals that possess anticoagulant or antiplatelet activity... 

C. Aspirin inhibits platelet cyclooxygenase. Abciximab, a monoclonal antibody, binds to and inhibits the platelet glycoprotein Ilb/IIIa receptor. Dipyridamole inhibits platelet cyclic AMP phosphodiesterase and raises cyclic AMP levels. Eptifibatide binds to the glycoprotein Ilb/IIIa complex. 

The UK manufacturer of eptifibatide reports that concurrent use with warfarin and dipyridamole did not appear to increase the risk of major and minor bleeding, and the use of heparin is recommended, but they warn that if eptifibatide is given with heparin, there must be careful monitoring including the aPTT. 

Caution must be employed when eptifibatide is used with other drugs that affect haemostasis, including clopidogrel, ticlopidine, dipyridamole, oral anticoagulants or thrombolytics and concurrent or planned use of another glycoprotein Ilb/IIIa inhibitor is contraindicated. ... 

---